BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• October
• November
• December

Day

• 1
• 2
• 5
• 6
• 7
• 8
• 9
• 12
• 13
• 14
• 15
• 16
• 19
• 20
• 21
• 22
• 23
• 27
• 28
• 29
• 30

• Lone Star Bio

  Genomic Health, Inc. Announces Study Results Demonstrating Oncotype DX(TM)'s Ability To Quantify Risk For Local And Regional Breast Cancer Recurrence

  December 12, 2005

   · 

  5 min read
• Pharm Country

  Hemispherx Biopharma To Present At The New York Society Of Security Analysts 9th Annual Healthcare Industry Conference

  December 12, 2005

   · 

  1 min read
• Drug Development

  Lorus Therapeutics Inc. Announces International Conference Presentation Of The Clinical Trial Of GTI-2040 Combined With High-dose Cytarabine In Acute Myeloid Leukemia

  December 12, 2005

   · 

  6 min read
• Bio NC

  New External Study Demonstrates Strong Correlation Of TriPath Imaging Inc.'s ProEx(TM) Br Biomarkers With Risk Of Breast Cancer Recurrence

  December 12, 2005

   · 

  5 min read
• Business

  NuGEN Technologies, Inc. Expands Management Team With Three New Appointments

  December 12, 2005

   · 

  1 min read
• Drug Development

  Celgene Release: Revlimid(R) Improves Overall Survival And Delays Time To Disease Progression In Previously Treated Multiple Myeloma Patients

  December 12, 2005

   · 

  7 min read
• FDA

  Lannett Company, Inc. Receives Approval For Doxycycline Monohydrate

  December 12, 2005

   · 

  1 min read
• Drug Development

  Geron Corporation Announces Data On The Effects Of Its Cancer Drug, GRN163L, On Multiple Myeloma At the American Society Of Hematology Annual Meeting

  December 12, 2005

   · 

  1 min read
• Drug Development

  OXiGENE Receives Regulatory Clearance To Commence Phase III Clinical Trial For Advanced, Inoperable Non-Small Cell Lung Cancer

  December 12, 2005

   · 

  1 min read
• CryoLife, Inc. Declares A Dividend Of Approximately $0.75 On Its Convertible Preferred Stock

  December 12, 2005

   · 

  1 min read